You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Becton Dickinson Co Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BECTON DICKINSON CO

BECTON DICKINSON CO has two approved drugs.

There are two US patents protecting BECTON DICKINSON CO drugs.

There are twenty patent family members on BECTON DICKINSON CO drugs in twelve countries.

Summary for Becton Dickinson Co
International Patents:20
US Patents:2
Tradenames:6
Ingredients:1
NDAs:2

Drugs and US Patents for Becton Dickinson Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Becton Dickinson Co CHLORAPREP WITH TINT chlorhexidine gluconate; isopropyl alcohol SPONGE;TOPICAL 020832-002 May 3, 2005 OTC Yes Yes 6,991,394 ⤷  Try for Free Y ⤷  Try for Free
Becton Dickinson Co CHLORAPREP ONE-STEP FREPP chlorhexidine gluconate; isopropyl alcohol SPONGE;TOPICAL 020832-003 Apr 26, 2002 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Becton Dickinson Co CHLORAPREP ONE-STEP chlorhexidine gluconate; isopropyl alcohol SPONGE;TOPICAL 020832-008 Oct 23, 2008 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Becton Dickinson Co CHLORAPREP ONE-STEP SEPP chlorhexidine gluconate; isopropyl alcohol SWAB;TOPICAL 021555-001 Oct 7, 2002 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Becton Dickinson Co CHLORAPREP SINGLE SWABSTICK chlorhexidine gluconate; isopropyl alcohol SWAB;TOPICAL 021555-002 May 10, 2005 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Becton Dickinson Co CHLORAPREP ONE-STEP chlorhexidine gluconate; isopropyl alcohol SPONGE;TOPICAL 020832-006 Nov 21, 2006 OTC Yes Yes 6,991,394 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Becton Dickinson Co

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Becton Dickinson Co Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: BECTON DICKINSON CO – Market Position, Strengths & Strategic Insights

In the ever-evolving world of medical technology, Becton Dickinson and Company (BD) stands as a titan, continuously shaping the landscape of healthcare innovation. As we delve into BD's market position, strengths, and strategic insights, we'll uncover the factors that have propelled this company to the forefront of the pharmaceutical and medical device industry.

BD's Market Position: A Global Leader in Medical Technology

Becton Dickinson and Company has established itself as a formidable force in the medical technology sector. With a diverse portfolio spanning medical supplies, devices, and diagnostic products, BD has secured a significant market share across various healthcare segments[1][2].

Revenue and Global Reach

BD's financial performance underscores its strong market position. In the fourth quarter of fiscal 2024, the company reported:

  • Revenue of $5.4 billion, a 6.9% increase year-over-year[7]
  • International operations generating 43% of total revenue[3]

This global footprint not only diversifies BD's revenue streams but also positions the company to capitalize on emerging markets and adapt to regional healthcare trends.

Segment Performance

BD's market position is further solidified by the strong performance across its three main segments:

  1. BD Medical
  2. BD Life Sciences
  3. BD Interventional

Each segment has shown resilience and growth, contributing to the company's overall market strength[7].

Core Strengths: The Pillars of BD's Success

BD's market leadership is built on a foundation of core strengths that set it apart from competitors.

Innovative Product Portfolio

At the heart of BD's success lies its commitment to innovation. The company's robust product lineup includes:

  • BD Alaris™ infusion systems
  • BD Pyxis™ medication management solutions
  • BD Vacutainer™ blood collection products
  • BD MAX™ molecular diagnostic systems

These products not only address critical healthcare needs but also drive efficiency and improve patient outcomes[1][4].

Research and Development Prowess

BD's strong R&D capabilities are a key differentiator in the competitive medical technology landscape. The company's focus on product development has led to:

  • Pioneering innovations in injection technologies
  • Advancements in diagnostic systems
  • Cutting-edge solutions in medication management[2]

Global Manufacturing and Distribution Network

BD's extensive manufacturing operations across Europe, Asia, and the Americas provide:

  • Supply chain resilience
  • Ability to quickly adapt to regional market demands
  • Cost-effective production and distribution[3]

Strategic Acquisitions and Partnerships

BD has strategically expanded its portfolio and capabilities through acquisitions, such as:

  • Edwards Lifesciences' Critical Care product group, enhancing BD's patient monitoring offerings[7]
  • Parata Systems, strengthening BD's pharmacy automation solutions[1]

These moves have allowed BD to enter new markets and enhance its existing product lines.

Competitive Landscape: Navigating a Complex Market

The medical technology industry is highly competitive, with several key players vying for market share. BD's main competitors include:

  • Thermo Fisher Scientific
  • Medtronic
  • Abbott Laboratories
  • Johnson & Johnson
  • Roche Diagnostics[6][9]

Each of these companies brings unique strengths to the table, pushing BD to continuously innovate and refine its strategies.

BD's Competitive Edge

Despite fierce competition, BD maintains its edge through:

  1. Diversified product portfolio spanning multiple healthcare segments
  2. Strong focus on high-growth markets like biologics and GLP-1s
  3. Continuous investment in R&D and new product development
  4. Global presence and strong brand recognition

Strategic Insights: BD's Path Forward

As BD looks to the future, several strategic initiatives are shaping its trajectory.

Focus on High-Growth Markets

BD is strategically aligning its resources to capitalize on high-growth areas within the healthcare sector. This includes:

  • Expanding its presence in the biologics market
  • Investing in solutions for emerging therapies like GLP-1s
  • Strengthening its position in vascular access management[4][7]

Leveraging Technological Advancements

BD is at the forefront of integrating cutting-edge technologies into healthcare solutions:

  • Artificial Intelligence (AI) integration in diagnostic systems
  • Automation solutions for pharmacies and laboratories
  • Advanced data analytics for improved patient care[7]

Operational Excellence through BD Excellence System

The company's commitment to operational efficiency is evident in its BD Excellence system, which aims to:

  • Streamline processes
  • Enhance margin expansion
  • Improve cash flow[7]

Sustainability and Corporate Responsibility

BD's strategic vision extends beyond financial performance to include:

  • Environmental sustainability initiatives
  • Social responsibility programs
  • Ethical governance practices

These efforts not only contribute to global health but also enhance BD's brand value and stakeholder trust.

SWOT Analysis: A Strategic Overview

To fully understand BD's position and potential, let's examine its strengths, weaknesses, opportunities, and threats.

Strengths

  • Diverse product portfolio
  • Strong global presence
  • Robust R&D capabilities
  • Brand recognition and reputation
  • Strategic acquisitions enhancing market position

Weaknesses

  • Reliance on sole-sourced materials
  • Supply chain vulnerabilities
  • Exposure to currency fluctuations due to global operations

Opportunities

  • Expansion in emerging markets
  • Growing demand for healthcare services globally
  • Advancements in healthcare technologies
  • Increasing focus on home healthcare and telemedicine

Threats

  • Intense competition in the medical technology sector
  • Regulatory challenges and changes
  • Economic uncertainties affecting healthcare spending
  • Potential supply chain disruptions
"We achieved another quarter, and another year, of strong performance through our talented team's execution of our BD2025 strategy and differentiated portfolio of medical technologies that are increasing healthcare efficiency and improving the lives of patients around the world," said Tom Polen, chairman, CEO and president of BD[1].

Future Outlook: Navigating Challenges and Opportunities

As BD moves forward, several factors will influence its trajectory:

Market Dynamics in China

BD faces challenges in the Chinese market, including:

  • Volume-based procurement affecting pricing
  • Transitory market dynamics impacting demand[1][4]

However, the company's global diversification helps mitigate these regional challenges.

Innovation Pipeline

BD's future growth is closely tied to its ability to bring innovative products to market. Key areas of focus include:

  • Advanced patient monitoring solutions
  • Next-generation diagnostic systems
  • Cutting-edge medication management technologies

Margin Expansion and Operational Efficiency

BD's commitment to operational excellence through its BD Excellence system positions the company to:

  • Improve profit margins
  • Enhance cash flow
  • Drive shareholder value[7]

Key Takeaways

  • BD maintains a strong market position as a global leader in medical technology, with a diverse product portfolio and significant international presence.
  • The company's core strengths lie in its innovative products, R&D capabilities, and strategic acquisitions.
  • BD faces intense competition but differentiates itself through its comprehensive healthcare solutions and focus on high-growth markets.
  • Strategic initiatives focusing on technological advancements, operational excellence, and sustainability are shaping BD's future trajectory.
  • While challenges exist, particularly in certain regional markets, BD's global diversification and strong innovation pipeline position it well for continued growth and market leadership.

FAQs

  1. What are BD's main business segments? BD operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. Each segment focuses on different aspects of healthcare and medical technology.

  2. How does BD maintain its competitive edge in the medical technology industry? BD maintains its competitive edge through continuous innovation, strategic acquisitions, a diverse product portfolio, and a strong global presence. The company's focus on high-growth markets and investment in R&D also contribute to its competitive advantage.

  3. What are some of BD's most innovative products? Some of BD's innovative products include the BD Alaris™ infusion systems, BD Pyxis™ medication management solutions, BD MAX™ molecular diagnostic systems, and BD Vacutainer™ blood collection products.

  4. How is BD addressing sustainability and corporate responsibility? BD has integrated sustainability and corporate responsibility into its strategic vision, focusing on environmental initiatives, social responsibility programs, and ethical governance practices. These efforts contribute to global health and enhance the company's brand value.

  5. What are the main challenges BD faces in the current market landscape? BD faces challenges such as intense competition, regulatory hurdles, economic uncertainties affecting healthcare spending, and potential supply chain disruptions. The company also needs to navigate market dynamics in regions like China, where volume-based procurement and other factors impact demand and pricing.

Sources cited: [1] https://investors.bd.com/news-events/press-releases/detail/802/bd-reports-fourth-quarter-and-full-year-fiscal-2023-financial-results [2] https://market.us/company/becton-dickinson-and-company/ [3] https://www.gurufocus.com/news/2619271/beyond-the-balance-sheet-what-swot-reveals-about-becton-dickinson-co-bdx [4] https://investors.bd.com/news-events/press-releases/detail/845/bd-reports-third-quarter-fiscal-2024-financial-results [6] https://pitchgrade.com/companies/becton-dickinson-and-co [7] https://investors.bd.com/news-events/press-releases/detail/859/bd-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results [9] https://pitchgrade.com/companies/becton-dickinson

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.